GCG and type 2 diabetes mellitus: As GIP and GLP-1 both have their protective effects and work together in cell signaling, novel GLP-1 and GIP receptor dual agonists are being developed and tested in clinical trials in patients with T2DM and show superior performance compared to liraglutide [205].